European Pharmaceutical Review

OCTOBER 20, 2022

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

Immunization 140

Immunization 140

Drug Topics

MARCH 26, 2024

Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.

Vaccines 199

Vaccines Immunization 199

pharmaphorum

JULY 26, 2021

While there are plenty of tests already available that can give a yes/no reading of whether antibodies are present, the Chembio test measures the level of antibodies as well, so can tell whether a patient is likely to be protected against the coronavirus. The post Rapid COVID immune status test launched in UK, Ireland appeared first on.

Immunization 137

Immunization Vaccines FDA 137

European Pharmaceutical Review

AUGUST 25, 2022

This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. 7 Studies also sought to modify oncolytic viruses with additional genes that more efficiently recruit the patient’s immune system to target tumour cells. suppressing activity.

Immunization 111

Immunization Chemotherapy Packaging 111

Pharmacy Times

OCTOBER 17, 2022

New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.

Immunization 65

Immunization FDA 65

BioPharm

APRIL 1, 2024

Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.

Immunization 52

Immunization 52

Pharmacy Times

MAY 2, 2024

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

Immunization 65

Immunization 65

pharmaphorum

NOVEMBER 4, 2021

While still preliminary, the experience with the two patients back up Talaris’ hope that giving a one-shot dose of FCR001 the day after an organ transplant could stimulate immune tolerance in the recipient, and avoid the side effects of current drug treatments such as infections, heart disease, and some forms of cancer.

Immunization 98

Immunization 98

Pharmacy Times

MAY 6, 2024

Merck presented results from the STRIDE-10 phase 3 trial at the 34th European Society of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Immunization 65

Immunization 65

Pharmacy Times

SEPTEMBER 19, 2024

Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.

Immunization 50

Immunization 50

Pharmacy Times

OCTOBER 3, 2023

In addition to the annual flu vaccines, COVID-19 boosters and RSV vaccines present new opportunities for pharmacists to advise patients.

Immunization 65

Immunization Vaccines 65

Pharma Mirror

FEBRUARY 18, 2021

A novel approach for ensuring the virtually unlimited production of QS-21, the ‘Gold Standard’ adjuvant for improving vaccine efficacy, will be the subject of an upcoming presentation at the BIO CEO & Investor Digital Conference, starting February 16.

Immunization 52

Immunization Vaccines 52

STAT

OCTOBER 29, 2024

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Cancer vaccines may also be able to help train the immune system to recognize and kill cancers related to viruses like HPV.

Vaccines 141

Vaccines Immunization 141

pharmaphorum

AUGUST 2, 2022

In May, another amyloid targeting drug for Alzheimer’s disease – AC Immune and Roche’s crenezumab – missed the mark in another clinical trial and looked destined for the scrap heap like so many drugs in the class before it. The post AC Immune tries to resurrect crenezumab with new data delve appeared first on.

Immunization 52

Immunization 52

STAT

FEBRUARY 29, 2024

At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, among people who got the Pfizer vaccine, although there were also cases detected among people who got the GSK product.

Vaccines 143

Vaccines Immunization 143

STAT

FEBRUARY 29, 2024

The vaccine effectiveness estimates, which showed unusually robust protection of children against influenza B viruses but more modest protection of people aged 65 and older against influenza A viruses, were presented Wednesday at a meeting of the CDC’s expert vaccine panel, the Advisory Committee on Immunization Practices.

Vaccines 112

Vaccines Immunization 112

pharmaphorum

APRIL 4, 2022

In particular, the findings suggest that disruption to innate immunity – the first line of defence against pathogens – as well as overly aggressive activity of white blood cells in the central nervous system called microglia. ” The post Study uncovers new Alzheimer’s genes, links to immune disruption appeared first on.

Immunization 52

Immunization 52

Pharmaceutical Technology

JUNE 6, 2023

PF-06835375 is a biologic commercialized by Pfizer, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV).

Immunization 40

Immunization Hospitals 40

STAT

APRIL 10, 2024

But as researchers from different companies and academic institutions presented promising early data at the American Association for Cancer Research annual meeting in San Diego this week, experts said there’s a collective feeling of turning a corner. SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade.

Vaccines 144

Vaccines Immunization 144

Pharmafile

APRIL 18, 2023

read more

Immunization 40

Immunization Vaccines 40

Pharmafile

APRIL 3, 2023

aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will present data at the World Vaccine Congress (WVC) in Washington, US. read more

Vaccines 72

Vaccines Immunization 72

Pharmaceutical Technology

FEBRUARY 24, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The post Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide? The net profit of the company was US$6,244.8

Pharmaceutical Companies 45

Pharmaceutical Companies Pharmaceutical Companies Immunization 45

The Checkup by Singlecare

SEPTEMBER 10, 2024

Administered annually (ideally before the flu season, which peaks from December to February in the United States), flu vaccines work by preparing the immune system to recognize and combat the flu effectively. Side effects happen because the vaccine is doing its job by activating the immune system,” says Dr. Zavala.

Vaccines 105

Vaccines Immunization Hospitals 105

STAT

OCTOBER 8, 2024

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to annoy. ” A U.S.

Compounding 82

Compounding FDA Compounding Pharmacies Vaccines 82

Pharmaceutical Technology

FEBRUARY 18, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The post Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab? appeared first on Pharmaceutical Technology.

Generic Medicine 40

Generic Medicine Immunization 40

STAT

FEBRUARY 22, 2023

The data were presented Wednesday to the Advisory Committee on Immunization Policy, which advises the Centers for Disease Control and Prevention. Read the rest…

Immunization 98

Immunization Hospitals Vaccines 98

Roots Analysis

DECEMBER 11, 2022

Presently, over 170 companies are engaged in the development of more than 970 early and late-stage T-cell therapies, worldwide. The post CAR-T Cell Therapies: Advancing Immune Cells to Treat Cancer appeared first on Blog. CAR-T Cell Therapies – Current Market Landscape.

Immunization 40

Immunization 40

STAT

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Immunization 111

Immunization 111

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.

Immunization 124

Immunization Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 124

NF2 BioSolutions

OCTOBER 4, 2024

As some of you may know, the focus of my PhD was to explore role of the immune system in VS, particularly a subset of immune cells known as T-cells. Along with PD-1, these T-cells expressed several other inhibitory molecules, all of which are targetable with immunotherapy-based drugs, like immune checkpoint blockade.

Immunization 111

Immunization Communication Hospitals 111

Pharmafile

OCTOBER 25, 2023

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory syncytial virus (RSV) vaccine, adjuvanted, in adults aged 50 to 59 including those at an increased risk of RSV lower respiratory tract disease (LRTD) due to underlying conditions.

Vaccines 59

Vaccines Immunization 59

European Pharmaceutical Review

DECEMBER 15, 2023

The companies previously presented data from KEYNOTE-942/mRNA-4157-P201, with a follow-up of approximately two years, at the American Association for Cancer Research (AACR) Annual Meeting, and the American Society of Clinical Oncology (ASCO) Annual Meeting. The most common adverse events were fatigue, injection site pain and chills.

Vaccines 115

Vaccines Research Laboratories Immunization 115

European Pharmaceutical Review

SEPTEMBER 20, 2023

Results of a Phase I/II study has revealed that a booster dose of a novel, self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine induces a robust, broadly cross-reactive, and durable immune response in adults. All three vaccines induced robust neutralising immune response against the D614G variant at Day 29.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

OCTOBER 25, 2024

the biologic has the potential to deliver anti-tumour responses in the majority of patients with ES-SCLC” The ongoing Phase I trial is assessing the antibody-drug conjugate both as a single treatment and as a combination therapy together with the immune checkpoint inhibitor atezolizumab.

Chemotherapy 96

Chemotherapy Compounding Immunization 96

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 110

Vaccines Immunization 110

Pharmaceutical Technology

SEPTEMBER 14, 2022

Before TIL infusion, the patient undergoes lymphodepletion, which reduces the proportion of myeloid immune suppressive cells and creates space for the incoming lymphocytes. The high level of neoantigens in melanoma makes this the ideal setting for TIL therapy, with tumours often containing multiple clones of tumour-reactive immune cells.

Immunization 98

Immunization 98

NF2 BioSolutions

OCTOBER 4, 2024

Over the last three years, we have been investigating how the body’s immune cells (which are usually the body’s natural defence system against infection) can actually play a role in driving tumour growth. Sporadic and NF2 VS are highly similar, specific macrophages found in growing VS, meningioma and VS have different immune profiles.

Immunization 105

Immunization Communication 105